Maravai LifeSciencesの空売り状況は、投資家がMaravai LifeSciencesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Maravai LifeSciences (NASDAQ:MRVI) 株価情報, 空売り情報

Maravai LifeSciences

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences Holdings Inc

<p><strong>Microvast Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Microvast Holdings will report an <strong>earnings per share</strong> (EPS) of $0.01. </p>
<p>Anticipation surrounds Microvast Holdings's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company beat EPS by $0.01, leading to a 32.48% increase in the share price the following trading session.</p>
<p>Here's a look at Microvast Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.02</td>
<td>0</td>
<td>-0.07</td>
<td>-0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.01</td>
<td>0.05</td>
<td>-0.21</td>
<td>-0.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>32.0%</td>
<td>340.0%</td>
<td>-14.000000000000002%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799393_0.png" alt="eps graph" /></p>
<h3>Performance of Microvast Holdings Shares</h3>
<p>Shares of Microvast Holdings were trading at $2.09 as of May 08. Over the last 52-week period, shares are up 389.87%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Opinions on Microvast Holdings</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Microvast Holdings.</p>
<p>A total of 1 analyst ratings have been received for Microvast Holdings, with the consensus rating being Buy. The average one-year price target stands at $3.0, suggesting a potential 43.54% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Douglas Dynamics, Astec Industries and Wabash National, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Douglas Dynamics, with an average 1-year price target of $32.0, suggesting a potential 1431.1% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Astec Industries, with an average 1-year price target of $41.0, suggesting a potential 1861.72% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Wabash National, with an average 1-year price target of $14.0, suggesting a potential 569.86% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Douglas Dynamics, Astec Industries and Wabash National are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microvast Holdings</td>
<td>Buy</td>
<td>8.43%</td>
<td>$41.52M</td>
<td>-18.35%</td>
</tr>
<tr>
<td>Douglas Dynamics</td>
<td>Buy</td>
<td>20.29%</td>
<td>$28.14M</td>
<td>0.05%</td>
</tr>
<tr>
<td>Astec Industries</td>
<td>Neutral</td>
<td>6.53%</td>
<td>$92.40M</td>
<td>2.22%</td>
</tr>
<tr>
<td>Wabash National</td>
<td>Neutral</td>
<td>-26.08%</td>
<td>$19.00M</td>
<td>77.93%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Microvast Holdings ranks at the bottom for Revenue Growth among its peers. It also ranks at the bottom for Gross Profit. However, it ranks at the top for Return on Equity.</p>
<h3>Get to Know Microvast Holdings Better</h3>
<p>Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.</p>
<h3>Unraveling the Financial Story of Microvast Holdings</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Microvast Holdings displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>8.43%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Microvast Holdings's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-72.6%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Microvast Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-18.35%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Microvast Holdings's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-8.35%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Microvast Holdings's debt-to-equity ratio is below the industry average at <strong>0.85</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/MVST/earnings"><strong>To track all earnings releases for Microvast Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

MVST

Earnings Outlook For Microvast Holdings

<p>Barclays  analyst Kannan Venkateshwar   maintains Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) with a Equal-Weight and raises the price target from $7 to $9.</p>


News

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Warner Bros. Discovery, Raises Price Target to $9

<p>Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) is preparing to release its quarterly earnings on Monday, 2025-05-12. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Legacy Housing to report an <strong>earnings per share</strong> (EPS) of $0.57.</p>
<p>Investors in Legacy Housing are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company beat EPS by $0.06, leading to a 2.67% increase in the share price the following trading session.</p>
<p>Here's a look at Legacy Housing's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.52</td>
<td>0.60</td>
<td>0.59</td>
<td>0.38</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.58</td>
<td>0.64</td>
<td>0.67</td>
<td>0.60</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>11.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799380_0.png" alt="eps graph" /></p>
<h3>Market Performance of Legacy Housing's Stock</h3>
<p>Shares of Legacy Housing were trading at $25.32 as of May 08. Over the last 52-week period, shares are up 9.77%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/LEGH/earnings"><strong>To track all earnings releases for Legacy Housing visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LEGH

Earnings Preview: Legacy Housing

<p>CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) is preparing to release its quarterly earnings on Monday, 2025-05-12. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect CompoSecure to report an <strong>earnings per share</strong> (EPS) of $0.19.</p>
<p>The announcement from CompoSecure is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS missed by $0.01 in the last quarter, leading to a 3.83% drop in the share price on the following day.</p>
<p>Here's a look at CompoSecure's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.21</td>
<td>0.29</td>
<td>0.25</td>
<td>0.25</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.20</td>
<td>0.27</td>
<td>0.27</td>
<td>0.25</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>-11.0%</td>
<td>28.999999999999996%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799372_0.png" alt="eps graph" /></p>
<h3>Market Performance of CompoSecure's Stock</h3>
<p>Shares of CompoSecure were trading at $11.56 as of May 08. Over the last 52-week period, shares are up 110.11%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CMPO/earnings"><strong>To track all earnings releases for CompoSecure visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CMPO

What's Next: CompoSecure's Earnings Preview

<p>HighPeak Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPK#NASDAQ">HPK</a>) is preparing to release its quarterly earnings on Monday, 2025-05-12. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect HighPeak Energy to report an <strong>earnings per share</strong> (EPS) of $0.34.</p>
<p>Anticipation surrounds HighPeak Energy's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.06, which was followed by a 7.37% drop in the share price the next day.</p>
<p>Here's a look at HighPeak Energy's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.13</td>
<td>0.22</td>
<td>0.50</td>
<td>0.37</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.19</td>
<td>0.35</td>
<td>0.28</td>
<td>0.37</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>11.0%</td>
<td>-2.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799363_0.png" alt="eps graph" /></p>
<h3>Performance of HighPeak Energy Shares</h3>
<p>Shares of HighPeak Energy were trading at $8.71 as of May 08. Over the last 52-week period, shares are down 36.41%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Insights Shared by Analysts on HighPeak Energy</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on HighPeak Energy.</p>
<p>Analysts have provided HighPeak Energy with 2 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $11.5, suggesting a potential 32.03% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Kimbell Royalty Partners, Kosmos Energy and Vitesse Energy, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Kimbell Royalty Partners, with an average 1-year price target of $16.0, suggesting a potential 83.7% upside.</li>
<li>Analysts currently favor an Buy trajectory for Kosmos Energy, with an average 1-year price target of $3.75, suggesting a potential 56.95% downside.</li>
<li>Analysts currently favor an Buy trajectory for Vitesse Energy, with an average 1-year price target of $30.5, suggesting a potential 250.17% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
<p>The peer analysis summary presents essential metrics for Kimbell Royalty Partners, Kosmos Energy and Vitesse Energy, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>HighPeak Energy</td>
<td>Neutral</td>
<td>-22.03%</td>
<td>$82.15M</td>
<td>0.51%</td>
</tr>
<tr>
<td>Kimbell Royalty Partners</td>
<td>Neutral</td>
<td>-16.16%</td>
<td>$35.13M</td>
<td>-4.64%</td>
</tr>
<tr>
<td>Kosmos Energy</td>
<td>Buy</td>
<td>-30.77%</td>
<td>$2.16M</td>
<td>-9.62%</td>
</tr>
<tr>
<td>Vitesse Energy</td>
<td>Buy</td>
<td>8.13%</td>
<td>$19.98M</td>
<td>0.46%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>HighPeak Energy ranks at the bottom for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.</p>
<h3>Unveiling the Story Behind HighPeak Energy</h3>
<p>HighPeak Energy Inc is an independent crude oil and natural gas company focused on the development of unconventional oil and natural gas reserves in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S.</p>
<h3>Financial Insights: HighPeak Energy</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> HighPeak Energy's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-22.03%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> HighPeak Energy's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.45%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> HighPeak Energy's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>0.51%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.26%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> HighPeak Energy's debt-to-equity ratio is below the industry average at <strong>0.66</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/HPK/earnings"><strong>To track all earnings releases for HighPeak Energy visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Outlook For HighPeak Energy

<p>MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) is preparing to release its quarterly earnings on Monday, 2025-05-12. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect MeridianLink to report an <strong>earnings per share</strong> (EPS) of $0.11.</p>
<p>The announcement from MeridianLink is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company missed EPS by $0.00, which was followed by a 16.6% increase in the share price the next day.</p>
<p>Here's a look at MeridianLink's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.08</td>
<td>0.08</td>
<td>0.08</td>
<td>0.07</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.08</td>
<td>0.06</td>
<td>0.04</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>17.0%</td>
<td>-1.0%</td>
<td>-5.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799353_0.png" alt="eps graph" /></p>
<h3>MeridianLink Share Price Analysis</h3>
<p>Shares of MeridianLink were trading at $17.23 as of May 08. Over the last 52-week period, shares are up 3.59%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<h3>Analysts' Perspectives on MeridianLink</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on MeridianLink.</p>
<p>A total of 5 analyst ratings have been received for MeridianLink, with the consensus rating being Neutral. The average one-year price target stands at $19.9, suggesting a potential 15.5% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Amplitude, NCR Voyix and TeraWulf, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Amplitude, with an average 1-year price target of $14.42, suggesting a potential 16.31% downside.</li>
<li>Analysts currently favor an Buy trajectory for NCR Voyix, with an average 1-year price target of $14.0, suggesting a potential 18.75% downside.</li>
<li>Analysts currently favor an Buy trajectory for TeraWulf, with an average 1-year price target of $6.0, suggesting a potential 65.18% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Amplitude, NCR Voyix and TeraWulf, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>MeridianLink</td>
<td>Neutral</td>
<td>6.51%</td>
<td>$52.81M</td>
<td>-1.83%</td>
</tr>
<tr>
<td>Amplitude</td>
<td>Buy</td>
<td>10.09%</td>
<td>$59.75M</td>
<td>-7.59%</td>
</tr>
<tr>
<td>NCR Voyix</td>
<td>Buy</td>
<td>-14.32%</td>
<td>$149M</td>
<td>-1.44%</td>
</tr>
<tr>
<td>TeraWulf</td>
<td>Buy</td>
<td>63.47%</td>
<td>$15.36M</td>
<td>-9.46%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>MeridianLink ranks in the middle for revenue growth among its peers. It has the lowest gross profit margin. The company has the highest return on equity compared to its peers. Overall, MeridianLink's performance is average when compared to its peers in the analysis.</p>
<h3>About MeridianLink</h3>
<p>MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.</p>
<h3>MeridianLink's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Positive Revenue Trend:</strong> Examining MeridianLink's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>6.51%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-9.75%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-1.83%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-0.8%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.1</strong>, MeridianLink faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/MLNK/earnings"><strong>To track all earnings releases for MeridianLink visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MLNK

Earnings Outlook For MeridianLink

<p>Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Xenon Pharmaceuticals will report an <strong>earnings per share</strong> (EPS) of $-0.91.</p>
<p>The announcement from Xenon Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.00, leading to a 3.37% drop in the share price on the subsequent day.</p>
<p>Here's a look at Xenon Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.84</td>
<td>-0.81</td>
<td>-0.70</td>
<td>-0.66</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.84</td>
<td>-0.81</td>
<td>-0.75</td>
<td>-0.62</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>-3.0%</td>
<td>-3.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799341_0.png" alt="eps graph" /></p>
<h3>Tracking Xenon Pharmaceuticals's Stock Performance</h3>
<p>Shares of Xenon Pharmaceuticals were trading at $35.54 as of May 08. Over the last 52-week period, shares are down 10.8%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/XENE/earnings"><strong>To track all earnings releases for Xenon Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


XENE

What to Expect from Xenon Pharmaceuticals's Earnings

<p><strong>Liberty Braves Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BATRK#NASDAQ">BATRK</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Liberty Braves Group will report an <strong>earnings per share</strong> (EPS) of $-0.85. </p>
<p>The market awaits Liberty Braves Group's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.17, leading to a 0.41% increase in the share price the following trading session.</p>
<p>Here's a look at Liberty Braves Group's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.48</td>
<td>0.02</td>
<td>0.38</td>
<td>-0.62</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.31</td>
<td>0.16</td>
<td>0.46</td>
<td>-0.83</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799334_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Liberty Braves Group were trading at $40.51 as of May 08. Over the last 52-week period, shares are up 7.37%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BATRK/earnings"><strong>To track all earnings releases for Liberty Braves Group visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BATRK

Liberty Braves Group Earnings Preview

<p>United Parks &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRKS#NYSE">PRKS</a>) is preparing to release its quarterly earnings on Monday, 2025-05-12. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect United Parks &amp; Resorts to report an <strong>earnings per share</strong> (EPS) of $-0.18.</p>
<p>United Parks &amp; Resorts bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.21, leading to a 6.28% drop in the share price on the subsequent day.</p>
<p>Here's a look at United Parks &amp; Resorts's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.71</td>
<td>2.22</td>
<td>1.54</td>
<td>-0.25</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.50</td>
<td>2.08</td>
<td>1.46</td>
<td>-0.17</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>3.0%</td>
<td>1.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799324_0.png" alt="eps graph" /></p>
<h3>Tracking United Parks &amp; Resorts's Stock Performance</h3>
<p>Shares of United Parks &amp; Resorts were trading at $45.85 as of May 08. Over the last 52-week period, shares are down 14.12%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/PRKS/earnings"><strong>To track all earnings releases for United Parks &amp; Resorts visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PRKS

Insights Ahead: United Parks & Resorts's Quarterly Earnings

<p>Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Archer Aviation will report an <strong>earnings per share</strong> (EPS) of $-0.22.</p>
<p>Investors in Archer Aviation are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS missed by $0.19 in the last quarter, leading to a 12.12% increase in the share price on the following day.</p>
<p>Here's a look at Archer Aviation's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.26</td>
<td>-0.32</td>
<td>-0.33</td>
<td>-0.33</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.45</td>
<td>-0.29</td>
<td>-0.32</td>
<td>-0.36</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>12.0%</td>
<td>11.0%</td>
<td>-9.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799316_0.png" alt="eps graph" /></p>
<h3>Tracking Archer Aviation's Stock Performance</h3>
<p>Shares of Archer Aviation were trading at $8.76 as of May 08. Over the last 52-week period, shares are up 135.2%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ACHR/earnings"><strong>To track all earnings releases for Archer Aviation visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ACHR

Preview: Archer Aviation's Earnings

<p>Imagine creating a money-generating AI agent and then confidently setting it loose without writing a single line of code. That's the premise behind Virtuals Protocol. The Ethereum L2 project makes it possible to build AI agents with distributed ownership and then run them in permissionless environments.</p>
<p>Three months after its debut, the price of the blockchain&#8217;s VIRTUAL governance token rocketed skyward, surging by 23,000% to $4.61 as developers rushed to test use cases and crypto traders waded in behind.</p>
<p>Markets brought it back to Earth in Q1 — but it&#8217;s surging again, up more than 300% in the past four weeks and more than 32% in the past seven days. Despite the robust move, at $2.14 (at time of writing) it's 59% under its all-time high of $5.25.</p>
<p>Still, VIRTUAL is back in demand. What's driving it?</p>
<h1 class="wp-block-heading">What is Virtuals Protocol?</h1>
<p>Launched last October on the Ethereum Layer 2 Base, Virtuals' innovative use of blockchain technology allows AI agents to be tokenized. That means their ownership can be shared and decentralized, then put to work in open, permissionless environments.</p>
<p>The project's <a href="https://whitepaper.virtuals.io/">white paper</a> calls Virtuals "a society of productive AI agents, each designed to generate services or products and autonomously engage in commerce — either with humans or other agents — onchain."</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09094433/VIRTUAL_1M_graph_coinmarketcap-1024x683.png" alt="" class="wp-image-12685" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09094433/VIRTUAL_1M_graph_coinmarketcap-1024x683.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09094433/VIRTUAL_1M_graph_coinmarketcap-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09094433/VIRTUAL_1M_graph_coinmarketcap-768x512.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09094433/VIRTUAL_1M_graph_coinmarketcap.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><em>Image: VIRTUAL one-month price trajectory &#x7C; Source: CoinMarketCap</em></p>
<p>What sets it apart from other agentic AI plays is the focus on democratisation. Instead of surrendering AI to Big Tech, Virtuals gives individual developers and smaller firms the power to create autonomous agents capable of communicating through text, speech, and animation while engaging dynamically with their virtual surroundings.</p>
<p>In a statement on the company website, Virtuals Protocol said it aims to create "a new economic model where AI agents are not just tools — they are community-owned assets that represent a blend of profit-driven incentives and decentralized governance."</p>
<p>An AI agent built on the platform could, for example, serve a dual role inside a gaming ecosystem like Roblox. In some games, it could be a virtual influencer. In others, it could be an interactive character. The agent/character/influencer would retain the memory of its interactions, promoting deeper engagement across games and use cases.</p>
<h1 class="wp-block-heading">How does Virtuals Protocol work?</h1>
<p>On Virtuals, an AI agent's ownership is represented by its token. When an AI agent is created on Virtuals, 1 billion tokens linked to that agent are minted and then added to a liquidity pool for users to buy.</p>
<p>In a sense, owning an agent token is like owning stock in a company. Each token represents a user's ownership share in that agent.</p>
<p>As more people interact with AI agents and pay for their service, value accrues to the token through a buyback-and-burn mechanism.</p>
<p>The protocol currently operates on Ethereum (ETH) and Base. Plans are underway to bring it Solana, potentially this year.</p>
<h1 class="wp-block-heading">First movers</h1>
<p>At time of writing, more than 16,000 AI agents had been deployed on the Virtuals Protocol with a <a href="https://dune.com/virtual_protocol/virtual-protocol-on-base">total market capitalization</a> of $675,387,503. The two most dominant agents are aixbt and GAME.</p>
<h2 class="wp-block-heading">1. aixbt</h2>
<p>Crypto analytics tool aixbt tracks crypto-related discussions on X (Twitter), engages in discussions, detects upcoming market trends, and highlights crypto alpha. At a market cap of $197.5 million, the AIXBT token is currently <a href="https://coinmarketcap.com/view/defai/">the most valuable</a> cryptocurrency in the decentralized finance artificial intelligence (DeFAI) category.</p>
<h2 class="wp-block-heading">2. GAME</h2>
<p>GAME (shirt for Generative Autonomous Multimodal Entities) is an AI agent developer platform for application in gaming environments like Roblox and Sandbox (SAND). At time of writing GAME had a market cap of $56.9 million.</p>
<h1 class="wp-block-heading">The takeaway</h1>
<p>Plans are now in the works to create a Virtuals <a href="https://whitepaper.virtuals.io/the-protocol/co-ownership-of-virtual-agents/agent-subdao-governance">governance </a>token that hands agent owners more power to approve new AI models and shape future standards.</p>
<p>VIRTUAL's recent surge highlights renewed interest in AI-driven crypto projects. If momentum continues, it could signal that markets believe blockchain-based agents are a viable mechanism for responsible AI development. As interest in decentralized AI grows, VIRTUAL could be on the cusp of deeper moves.</p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Global

Opinion

Trading Ideas

VIRTUAL Is Surging Again. Can Crypto's Agentic AI Mashup Sustain Its Momentum?

<p>Barclays  analyst Richard Hightower   maintains UDR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>) with a Overweight and raises the price target from $48 to $51.</p>


Barclays Maintains Overweight on UDR, Raises Price Target to $51

<p><strong>NRG Energy</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that NRG Energy will report an <strong>earnings per share</strong> (EPS) of $1.62. </p>
<p>The announcement from NRG Energy is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS beat by $0.23, leading to a 7.25% drop in the share price on the subsequent day.</p>
<p>Here's a look at NRG Energy's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.29</td>
<td>2</td>
<td>1.59</td>
<td>0.88</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.52</td>
<td>1.85</td>
<td>3.37</td>
<td>2.31</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>-0.0%</td>
<td>3.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799303_0.png" alt="eps graph" /></p>
<h3>Market Performance of NRG Energy's Stock</h3>
<p>Shares of NRG Energy were trading at $120.34 as of May 08. Over the last 52-week period, shares are up 44.71%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Opinions on NRG Energy</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on NRG Energy.</p>
<p>The consensus rating for NRG Energy is Buy, derived from 6 analyst ratings. An average one-year price target of $130.83 implies a potential 8.72% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of FirstEnergy, Eversource Energy and PPL, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for FirstEnergy, with an average 1-year price target of $45.0, suggesting a potential 62.61% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Eversource Energy, with an average 1-year price target of $65.0, suggesting a potential 45.99% downside.</li>
<li>Analysts currently favor an Neutral trajectory for PPL, with an average 1-year price target of $37.5, suggesting a potential 68.84% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for FirstEnergy, Eversource Energy and PPL, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRG Energy</td>
<td>Buy</td>
<td>0.18%</td>
<td>$1.95B</td>
<td>33.91%</td>
</tr>
<tr>
<td>FirstEnergy</td>
<td>Neutral</td>
<td>14.54%</td>
<td>$2.53B</td>
<td>2.88%</td>
</tr>
<tr>
<td>Eversource Energy</td>
<td>Neutral</td>
<td>23.58%</td>
<td>$2.29B</td>
<td>3.63%</td>
</tr>
<tr>
<td>PPL</td>
<td>Neutral</td>
<td>8.68%</td>
<td>$1.11B</td>
<td>2.91%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>NRG Energy ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. NRG Energy is at the top for Return on Equity.</p>
<h3>Delving into NRG Energy's Background</h3>
<p>NRG Energy is one of the largest retail energy providers in the us, with 6 million customers. Vivint Smart Home, which NRG acquired in 2023, has 2 million home services customers. NRG also is one of the largest us independent power producers, with 13 gigawatts of coal, gas, and oil power generation capacity primarily in Texas. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.</p>
<h3>NRG Energy: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> NRG Energy's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>0.18%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Utilities sector.</p>
<p><strong>Net Margin:</strong> NRG Energy's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>9.19%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> NRG Energy's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>33.91%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> NRG Energy's ROA excels beyond industry benchmarks, reaching <strong>2.63%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>6.01</strong>, NRG Energy faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/NRG/earnings"><strong>To track all earnings releases for NRG Energy visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


NRG Energy's Earnings: A Preview

<p>DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that DaVita will report an <strong>earnings per share</strong> (EPS) of $2.08.</p>
<p>The announcement from DaVita is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.10, leading to a 11.09% drop in the share price the following trading session.</p>
<p>Here's a look at DaVita's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.14</td>
<td>2.73</td>
<td>2.54</td>
<td>1.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.24</td>
<td>2.59</td>
<td>2.59</td>
<td>2.38</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-11.0%</td>
<td>-11.0%</td>
<td>-2.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799295_0.png" alt="eps graph" /></p>
<h3>Tracking DaVita's Stock Performance</h3>
<p>Shares of DaVita were trading at $143.63 as of May 08. Over the last 52-week period, shares are up 5.06%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on DaVita</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on DaVita.</p>
<p>The consensus rating for DaVita is Neutral, derived from 1 analyst ratings. An average one-year price target of $169.0 implies a potential 17.66% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Hims &amp; Hers Health, Chemed and Option Care Health, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Hims &amp; Hers Health, with an average 1-year price target of $37.11, suggesting a potential 74.16% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Chemed, with an average 1-year price target of $670.5, suggesting a potential 366.82% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Option Care Health, with an average 1-year price target of $38.5, suggesting a potential 73.2% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for Hims &amp; Hers Health, Chemed and Option Care Health are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>DaVita</td>
<td>Neutral</td>
<td>4.73%</td>
<td>$1.07B</td>
<td>102.13%</td>
</tr>
<tr>
<td>Hims &amp; Hers Health</td>
<td>Neutral</td>
<td>110.67%</td>
<td>$430.69M</td>
<td>9.65%</td>
</tr>
<tr>
<td>Chemed</td>
<td>Outperform</td>
<td>9.79%</td>
<td>$216.41M</td>
<td>6.24%</td>
</tr>
<tr>
<td>Option Care Health</td>
<td>Outperform</td>
<td>16.31%</td>
<td>$263.05M</td>
<td>3.39%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>DaVita ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.</p>
<h3>About DaVita</h3>
<p>DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.</p>
<h3>A Deep Dive into DaVita's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining DaVita's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>4.73%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> DaVita's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>7.87%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>102.13%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> DaVita's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.49%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> DaVita's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>99.63</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<p><a href="https://www.benzinga.com/quote/DVA/earnings"><strong>To track all earnings releases for DaVita visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Outlook For DaVita

<p>Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) in the last three months.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Brighthouse Finl and provided 12-month price targets. The average target is $60.86, accompanied by a high estimate of $76.00 and a low estimate of $41.00. Observing a 7.72% increase, the current average has risen from the previous average price target of $56.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799294_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Brighthouse Finl among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$76.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$52.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$41.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Wilma Burdis</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Strong Buy</td>
<td>$72.00</td>
<td>-</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$59.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$66.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$52.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Brighthouse Finl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Brighthouse Finl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Brighthouse Finl's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Brighthouse Finl's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BHF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Brighthouse Finl analyst ratings.</strong></a></p>
<h2>About Brighthouse Finl</h2>
<p>Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.</p>
<h3>Brighthouse Finl's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Brighthouse Finl's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-20.93%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>59.98%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Brighthouse Finl's ROE excels beyond industry benchmarks, reaching <strong>12.32%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Brighthouse Finl's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.27%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Brighthouse Finl's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.64</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Brighthouse Financial, Inc. - Common Stock

7 Analysts Assess Brighthouse Finl: What You Need To Know

<p>Deep-pocketed investors have adopted a bearish approach towards UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UNH usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for UnitedHealth Group. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 40% leaning bullish and 45% bearish. Among these notable options, 6 are puts, totaling $596,747, and 14 are calls, amounting to $676,501.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $350.0 to $530.0 for UnitedHealth Group over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for UnitedHealth Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across UnitedHealth Group's significant trades, within a strike price range of $350.0 to $530.0, over the past month.</p>
<h3>UnitedHealth Group 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799287_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$144.4</td>
<td>$141.0</td>
<td>$144.4</td>
<td>$530.00</td>
<td>$288.8K</td>
<td>768</td>
<td align="right">20</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$74.0</td>
<td>$72.7</td>
<td>$74.0</td>
<td>$460.00</td>
<td>$148.0K</td>
<td>673</td>
<td align="right">9</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/09/25</td>
<td>$36.3</td>
<td>$33.3</td>
<td>$35.5</td>
<td>$350.00</td>
<td>$88.7K</td>
<td>110</td>
<td align="right">25</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$13.1</td>
<td>$13.0</td>
<td>$13.01</td>
<td>$500.00</td>
<td>$65.0K</td>
<td>2.6K</td>
<td align="right">117</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.3</td>
<td>$3.0</td>
<td>$3.12</td>
<td>$395.00</td>
<td>$62.4K</td>
<td>319</td>
<td align="right">739</td>
</tr>
</tbody>
</table>
</p>
<h3>About UnitedHealth Group</h3>
<p>UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.</p>
<p>Having examined the options trading patterns of UnitedHealth Group, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is UnitedHealth Group Standing Right Now?</h3>
<ul>
<li>With a volume of 887,941, the price of UNH is down -0.34% at $384.24. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 67 days.</li>
</ul>
<h3>What Analysts Are Saying About UnitedHealth Group</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $539.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Baird persists with their Outperform rating on UnitedHealth Group, maintaining a target price of $510.<br />
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for UnitedHealth Group, targeting a price of $525.<br />
&#x2A; An analyst from JP Morgan persists with their Overweight rating on UnitedHealth Group, maintaining a target price of $525.<br />
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on UnitedHealth Group, which currently sits at a price target of $560.<br />
&#x2A; An analyst from Keybanc persists with their Overweight rating on UnitedHealth Group, maintaining a target price of $575. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for UnitedHealth Group, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

Looking At UnitedHealth Group's Recent Unusual Options Activity

<p>Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) in the last three months.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $194.25, a high estimate of $251.00, and a low estimate of $160.00. This upward trend is apparent, with the current average reflecting a 6.32% increase from the previous average price target of $182.71.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799285_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A comprehensive examination of how financial experts perceive Natera is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$251.00</td>
<td>-</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$188.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Natera. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Natera compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Natera's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Natera's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NTRA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Natera analyst ratings.</strong></a></p>
<h2>Discovering Natera: A Closer Look</h2>
<p>Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.</p>
<h3>Understanding the Numbers: Natera's Finances</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Natera's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>53.02%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Natera's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-11.29%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-5.19%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Natera's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-3.31%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.16</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NTRA

8 Analysts Have This To Say About Natera

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Palantir Technologies</strong>.</p>
<p>Looking at options history for Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) we detected 14 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 64% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $260,202 and 9, calls, for a total amount of $364,109.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $100.0 to $125.0 for Palantir Technologies over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Palantir Technologies's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Palantir Technologies's significant trades, within a strike price range of $100.0 to $125.0, over the past month.</p>
<h3>Palantir Technologies 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799282_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$25.15</td>
<td>$25.05</td>
<td>$25.15</td>
<td>$120.00</td>
<td>$125.7K</td>
<td>1.5K</td>
<td align="right">70</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$21.65</td>
<td>$19.4</td>
<td>$20.87</td>
<td>$100.00</td>
<td>$62.6K</td>
<td>169</td>
<td align="right">0</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$5.5</td>
<td>$5.35</td>
<td>$5.5</td>
<td>$115.00</td>
<td>$55.0K</td>
<td>10.0K</td>
<td align="right">736</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$4.0</td>
<td>$3.95</td>
<td>$4.0</td>
<td>$117.00</td>
<td>$48.8K</td>
<td>1.9K</td>
<td align="right">649</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.4</td>
<td>$9.25</td>
<td>$9.25</td>
<td>$120.00</td>
<td>$46.2K</td>
<td>13.0K</td>
<td align="right">77</td>
</tr>
</tbody>
</table>
</p>
<h3>About Palantir Technologies</h3>
<p>Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.</p>
<p>In light of the recent options history for Palantir Technologies, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Palantir Technologies's Current Market Status</h3>
<ul>
<li>With a trading volume of 13,235,897, the price of PLTR is down by -1.4%, reaching $117.48.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 87 days from now.</li>
</ul>
<h3>Expert Opinions on Palantir Technologies</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $98.4.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from DA Davidson has decided to maintain their Neutral rating on Palantir Technologies, which currently sits at a price target of $100.<br />
&#x2A; An analyst from UBS has decided to maintain their Neutral rating on Palantir Technologies, which currently sits at a price target of $110.<br />
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Palantir Technologies, targeting a price of $90.<br />
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Underperform rating for Palantir Technologies, targeting a price of $94.<br />
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Palantir Technologies, maintaining a target price of $98. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Palantir Technologies, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


PLTR

Palantir Technologies Unusual Options Activity

<p>High-rolling investors have positioned themselves bearish on JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in JD often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 10 options trades for JD.com. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 40% bullish and 60% bearish. Among all the options we identified, there was one put, amounting to $64,130, and 9 calls, totaling $481,039.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $38.0 for JD.com over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in JD.com's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to JD.com's substantial trades, within a strike price spectrum from $25.0 to $38.0 over the preceding 30 days.</p>
<h3>JD.com Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799276_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$13.15</td>
<td>$13.0</td>
<td>$13.0</td>
<td>$25.00</td>
<td>$128.7K</td>
<td>1.2K</td>
<td align="right">145</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$13.0</td>
<td>$12.85</td>
<td>$13.0</td>
<td>$25.00</td>
<td>$65.0K</td>
<td>1.2K</td>
<td align="right">95</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.3</td>
<td>$5.2</td>
<td>$5.3</td>
<td>$35.00</td>
<td>$64.1K</td>
<td>2.7K</td>
<td align="right">121</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$13.0</td>
<td>$12.8</td>
<td>$13.0</td>
<td>$25.00</td>
<td>$58.5K</td>
<td>1.2K</td>
<td align="right">0</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$2.37</td>
<td>$2.1</td>
<td>$2.1</td>
<td>$35.00</td>
<td>$55.6K</td>
<td>23.4K</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About JD.com</h3>
<p>JD.com is the third-largest Chinese e-commerce platform by GMV in 2024. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.</p>
<h3>Present Market Standing of JD.com</h3>
<ul>
<li>Trading volume stands at 1,107,276, with JD's price up by 0.5%, positioned at $34.29.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 4 days.</li>
</ul>
<h3>What Analysts Are Saying About JD.com</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $44.67.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on JD.com with a target price of $48.<br />
&#x2A; Reflecting concerns, an analyst from Macquarie lowers its rating to Neutral with a new price target of $35.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on JD.com with a target price of $51. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest JD.com options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Smart Money Is Betting Big In JD.com Options

<p>In the latest quarter, 9 analysts provided ratings for Camden Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPT#NYSE">CPT</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $131.56, with a high estimate of $139.00 and a low estimate of $123.00. Marking an increase of 6.1%, the current average surpasses the previous average price target of $124.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746799275_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of Camden Prop Trust by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$136.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$127.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Nick Joseph</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$138.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$129.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Linda Tsai</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$139.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$123.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$127.00</td>
<td>$118.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Camden Prop Trust. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Camden Prop Trust compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Camden Prop Trust's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Camden Prop Trust's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Camden Prop Trust analyst ratings.</strong></a></p>
<h2>Delving into Camden Prop Trust's Background</h2>
<p>Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 177 multifamily properties comprised of nearly 59,996 apartment homes across the United States.</p>
<h3>Unraveling the Financial Story of Camden Prop Trust</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Camden Prop Trust displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>1.94%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>9.92%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Camden Prop Trust's ROE excels beyond industry benchmarks, reaching <strong>0.83%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Camden Prop Trust's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.43%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Camden Prop Trust's debt-to-equity ratio is below the industry average. With a ratio of <b>0.81</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: Camden Prop Trust In The Eyes Of 9 Experts

Press Releases

Levi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 - MRVI

Legal

Levi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 – MRVI

The Gross Law Firm Notifies Maravai LifeSciences Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRVI

MRVI Shareholders Have Opportunity to Lead the Maravai LifeSciences Holdings, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - MRVI

Penny Stocks

Small Cap

MRVI Investors Reminded of Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm

MRVI DEADLINE TODAY: Maravai LifeSciences (MRVI) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Maravai LifeSciences Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRVI

Comments

Maravai LifeSciences

空売り

Maravai LifeSciences (NASDAQ:MRVI) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル